Aclaris therapeutics announces patent license agreement with lilly for alopecia areata

Wayne, pa., aug. 25, 2022 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with eli lilly and company (lilly).
ACRS Ratings Summary
ACRS Quant Ranking